Precision BioSciences Inc (DTIL)
10.48
+0.64
(+6.50%)
USD |
NASDAQ |
Apr 30, 16:00
10.48
0.00 (0.00%)
After-Hours: 20:00
Precision BioSciences Cash from Financing (TTM): 5.387M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 5.387M |
September 30, 2023 | 2.559M |
June 30, 2023 | 2.413M |
March 31, 2023 | 93.48M |
December 31, 2022 | 94.98M |
September 30, 2022 | 103.36M |
June 30, 2022 | 115.46M |
March 31, 2022 | 36.06M |
December 31, 2021 | 70.52M |
September 30, 2021 | 62.34M |
June 30, 2021 | 50.96M |
Date | Value |
---|---|
March 31, 2021 | 37.73M |
December 31, 2020 | 1.329M |
September 30, 2020 | 1.837M |
June 30, 2020 | 1.366M |
March 31, 2020 | 135.39M |
December 31, 2019 | 173.37M |
September 30, 2019 | 171.08M |
June 30, 2019 | 192.33M |
March 31, 2019 | 146.05M |
December 31, 2018 | 107.78M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
1.329M
Minimum
Dec 2020
192.33M
Maximum
Jun 2019
71.16M
Average
62.34M
Median
Sep 2021
Cash from Financing (TTM) Benchmarks
Altimmune Inc | 86.10M |
BioVie Inc | 15.36M |
Adial Pharmaceuticals Inc | 4.132M |
Gritstone Bio Inc | 25.12M |
Humacyte Inc | 4.507M |